PYC Therapeutics (Australia) Investor Sentiment

PYC Stock   1.40  0.05  3.45%   
Slightly above 62% of PYC Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding PYC Therapeutics suggests that many traders are alarmed. PYC Therapeutics' investing sentiment can be driven by a variety of factors including economic data, PYC Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
over six months ago at news.google.com         
Pyc Therapeutics Limited Share Price Latest News - The Market Online - The Market Herald
Google News at Macroaxis
over six months ago at news.google.com         
PYC Therapeutics CEO Executive Director Rohan Hockings Sells 100 percent Of Holding - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
PYC Therapeutics enters into collaboration with Google Cloud for AI-driven precision medicine - Smal...
Google News at Macroaxis
over six months ago at news.google.com         
Why Arcadium Lithium, IAG, PYC Therapeutics, and Zip shares are falling today - The Motley Fool Aust...
Google News at Macroaxis
over six months ago at news.google.com         
PYC Therapeutics Insiders Placed Bullish Bets Worth AU15.1m - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Owning 57 percent in PYC Therapeutics Limited means that insiders are heavily invested in the compan...
Google News at Macroaxis
over a year ago at news.google.com         
PYC Therapeutics Insider Buyers See Boost After Market Cap Rose AU41m - Simply Wall St
Google News at Macroaxis
over a year ago at news.google.com         
Hot Money Monday Momentum trading has been a popular strategy for decades, and heres how you can u ....
Google News at Macroaxis
over a year ago at news.google.com         
Dr Borehams Crucible PYC Therapeutics - FN Arena News
Google News at Macroaxis
over a year ago at news.google.com         
Should Shareholders Worry About PYC Therapeutics Limiteds CEO Compensation Package - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
ASX Health Stocks 4DX skyrockets 54pc after US update on its XV LVAS scanning device - Stockhead
Google News at Macroaxis
over a year ago at news.google.com         
Cannabis driving test CBD without THC - The Cairns Post
Google News at Macroaxis
over a year ago at news.google.com         
ASX Health Stocks PYC on the same page with FDA, Cleos cancer test peer-reviewed - Stockhead
Google News at Macroaxis
over a year ago at news.google.com         
Heres Why Were Watching PYC Therapeutics Cash Burn Situation - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
PYC Therapeutics shareholders have earned a 16 percent CAGR over the last five years - Yahoo Finance
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about PYC Therapeutics that are available to investors today. That information is available publicly through PYC media outlets and privately through word of mouth or via PYC internal channels. However, regardless of the origin, that massive amount of PYC data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of PYC Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of PYC Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to PYC Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive PYC Therapeutics alpha.

PYC Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Insider Stock Buying Of PYC Therapeutics Delivers Return On AU5.25m Investment - Yahoo Finance
10/28/2024
2
PYC Therapeutics Announces Security Consolidation Plan - MSN
11/20/2024
3
PYC Therapeutics Announces Share Consolidation Impact - TipRanks
11/26/2024

Additional Tools for PYC Stock Analysis

When running PYC Therapeutics' price analysis, check to measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.